Retacrit Shortage: What Providers and Prescribers Need to Know in 2026

Retacrit (epoetin alfa-epbx), the first FDA-approved biosimilar erythropoiesis-stimulating agent (ESA) in the U.S., has experienced repeated supply disruptions since its 2018 launch. For prescribers managing patients with CKD-related anemia, chemotherapy-induced anemia, or HIV-associated anemia, these disruptions create real clinical challenges. This article provides a comprehensive overview of what providers need to know about Retacrit supply issues in 2026.

Current Supply Status (2026)

According to ASHP's Drug Shortage Database (updated June 27, 2025), Pfizer has Retacrit available in the market. No active national shortage is declared for Retacrit heading into 2026. However, clinicians should be aware of several important nuances:

• Epogen (Amgen) has experienced documented shortages of certain strengths, which may increase demand for Retacrit and create downstream stocking pressure
• Individual vial strengths (particularly 2,000 or 3,000 Units/mL) may have uneven regional availability
• Specialty pharmacy and dialysis center inventory varies significantly by distributor and region

Retacrit Supply Disruption History

Clinicians should understand the prior disruption history when advising patients and planning contingencies:

• Q2–Q4 2022: Pfizer notified payers in March 2022 of a supply disruption beginning late May 2022, with resolution targeted by Q4 2022. This forced transitions to Epogen and Procrit for many patients.
• September 2023: A second disruption prompted multiple payers to suspend Retacrit as their preferred ESA and revert to Epogen/Procrit under the medical benefit.
• 2024–2026: Supply normalized, with no formal shortage declaration. Retacrit remains available from Pfizer.

Formulary and Payer Considerations

Retacrit has largely displaced Epogen and Procrit as the preferred ESA on commercial and Medicaid formularies due to its lower acquisition cost. Key payer dynamics in 2026:

• UnitedHealthcare: Retacrit is the preferred ESA; members already on Epogen/Procrit are required to transition to Retacrit unless a clinical exception applies.
• Most commercial plans require prior authorization for Retacrit based on indication, hemoglobin threshold (typically Hgb <10 g/dL), and iron store documentation (ferritin ≥100 ng/mL and TSAT ≥20%).
• Medicare billing: Retacrit is typically billed under Part B as HCPCS code Q5106 (non-ESRD use) or Q5105 (ESRD on dialysis). Medical benefit claims are processed differently from pharmacy benefit claims.
• Note: Retacrit is NOT FDA-designated as interchangeable with Epogen or Procrit. Any product switch requires a new prescription from the prescriber — pharmacists cannot auto-substitute.

Clinical Management Strategies During Supply Disruptions

When Retacrit is unavailable, providers should implement a structured transition protocol:

1. Identify affected patients proactively. Generate a list of patients currently on Retacrit and review their most recent hemoglobin levels and remaining supply. Prioritize patients with hemoglobin levels close to threshold (<10 g/dL).
2. Switch to Epogen or Procrit (same molecule). For most patients, a 1:1 unit-for-unit dose conversion is appropriate when switching between epoetin alfa products (Retacrit → Epogen or Procrit). Issue a new prescription for the alternative product.
3. Consider Aranesp (darbepoetin alfa) for eligible patients. Aranesp is approved for CKD and chemotherapy anemia (not HIV or surgery). Use the established conversion table: 200 Units/week of epoetin alfa ≈ 1 mcg/week of darbepoetin alfa. Weekly or biweekly dosing reduces injection burden.
4. Obtain prior authorization early. During shortage periods, payers often implement expedited PA processes. Work with your pharmacy team to submit shortage-related prior authorization documentation quickly. Reference ASHP shortage documentation when applicable.
5. Increase hemoglobin monitoring frequency. During any ESA transition, monitor hemoglobin weekly until stable. Watch for rapid changes in either direction.

ESA Alternatives: Clinical Comparison for Providers

Epogen / Procrit (epoetin alfa): Identical active ingredient; 1:1 dose conversion; all same indications as Retacrit; IV or SC; 3x/week typical dosing. New prescription required.

Aranesp (darbepoetin alfa): Different molecule; dose conversion required (200 units/week epoetin alfa ≈ 1 mcg/week darbepoetin); CKD and chemo indications only; weekly to Q3W dosing; not for HIV or surgery.

Mircera (methoxy PEG-epoetin beta): CKD only; monthly or biweekly; conversion tables available; good option for stable CKD dialysis patients.

How medfinder Helps Providers During Drug Shortages

When your patients need to locate Retacrit or transition to an alternative at a pharmacy, medfinder for providers can help streamline the process. medfinder calls specialty pharmacies on behalf of patients to check which ones have the required medication and strength in stock — reducing the burden on your front office staff while helping patients avoid treatment gaps.

The Bottom Line for Providers

Retacrit supply appears stable heading into 2026, but its history of disruptions warrants proactive planning. Maintain current patient lists, confirm PA approvals early, and have a clear protocol ready for transitions to Epogen, Procrit, or Aranesp. See our provider guide on helping patients find Retacrit in stock for additional practice management strategies.